ALSEN.PA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 23:01):

Stats
今日成交量	34 738.00
平均成交量	120 249
市值	210.67M
EPS	€0 ( 2024-03-14 )
下一个收益日期	( €0 ) 2024-05-23
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-4.13
ATR14	€0.00400 (0.57%)

Sensorion SA 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Sensorion SA 财务报表

Annual	2023
营收:	€4.74M
毛利润:	€3.79M (79.86 %)
EPS:	€-0.170

FY	2023
营收:	€4.74M
毛利润:	€3.79M (79.86 %)
EPS:	€-0.170

FY	2022
营收:	€4.93M
毛利润:	€4.16M (84.38 %)
EPS:	€-0.290

FY	2021
营收:	€3.34M
毛利润:	€0.00 (0.00 %)
EPS:	€-0.190

Financial Reports:

No articles found.

Sensorion SA

Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.